These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 27726306)
1. CXCL9: evidence and contradictions for its role in tumor progression. Ding Q; Lu P; Xia Y; Ding S; Fan Y; Li X; Han P; Liu J; Tian D; Liu M Cancer Med; 2016 Nov; 5(11):3246-3259. PubMed ID: 27726306 [TBL] [Abstract][Full Text] [Related]
2. The Multifaceted Roles of CXCL9 Within the Tumor Microenvironment. Neo SY; Lundqvist A Adv Exp Med Biol; 2020; 1231():45-51. PubMed ID: 32060845 [TBL] [Abstract][Full Text] [Related]
3. CXCR3, a double-edged sword in tumor progression and angiogenesis. Billottet C; Quemener C; Bikfalvi A Biochim Biophys Acta; 2013 Dec; 1836(2):287-95. PubMed ID: 23994549 [TBL] [Abstract][Full Text] [Related]
4. Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production. Whiting D; Hsieh G; Yun JJ; Banerji A; Yao W; Fishbein MC; Belperio J; Strieter RM; Bonavida B; Ardehali A J Immunol; 2004 Jun; 172(12):7417-24. PubMed ID: 15187119 [TBL] [Abstract][Full Text] [Related]
5. Herpes Simplex Virus Type 2 Infection-Induced Expression of CXCR3 Ligands Promotes CD4 Zhang M; Deng X; Guan X; Geng L; Fu M; Zhang B; Chen R; Hu H; Hu K; Zhang D; Li M; Liu Y; Gong S; Hu Q Front Immunol; 2018; 9():2932. PubMed ID: 30619292 [TBL] [Abstract][Full Text] [Related]
6. Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity--a tale of conflict and conundrum. Müller M; Carter S; Hofer MJ; Campbell IL Neuropathol Appl Neurobiol; 2010 Aug; 36(5):368-87. PubMed ID: 20487305 [TBL] [Abstract][Full Text] [Related]
7. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Wasmuth HE; Lammert F; Zaldivar MM; Weiskirchen R; Hellerbrand C; Scholten D; Berres ML; Zimmermann H; Streetz KL; Tacke F; Hillebrandt S; Schmitz P; Keppeler H; Berg T; Dahl E; Gassler N; Friedman SL; Trautwein C Gastroenterology; 2009 Jul; 137(1):309-19, 319.e1-3. PubMed ID: 19344719 [TBL] [Abstract][Full Text] [Related]
9. Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T cells in lymphocyte-rich gastric carcinoma. Ohtani H; Jin Z; Takegawa S; Nakayama T; Yoshie O J Pathol; 2009 Jan; 217(1):21-31. PubMed ID: 18980207 [TBL] [Abstract][Full Text] [Related]
10. MIG in Cutaneous Systemic Lupus Erythematosus. Ruffilli I Clin Ter; 2019; 170(1):e71-e76. PubMed ID: 30789201 [TBL] [Abstract][Full Text] [Related]
11. CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer. Zhang C; Li Z; Xu L; Che X; Wen T; Fan Y; Li C; Wang S; Cheng Y; Wang X; Qu X; Liu Y BMC Cancer; 2018 Apr; 18(1):462. PubMed ID: 29690901 [TBL] [Abstract][Full Text] [Related]
12. CXCL9 causes heterologous desensitization of CXCL12-mediated memory T lymphocyte activation. Giegold O; Ogrissek N; Richter C; Schröder M; Herrero San Juan M; Pfeilschifter JM; Radeke HH J Immunol; 2013 Apr; 190(7):3696-705. PubMed ID: 23447686 [TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. Marx N; Mach F; Sauty A; Leung JH; Sarafi MN; Ransohoff RM; Libby P; Plutzky J; Luster AD J Immunol; 2000 Jun; 164(12):6503-8. PubMed ID: 10843708 [TBL] [Abstract][Full Text] [Related]
14. Rheumatoid arthritis and the Th1 chemokine MIG. Paparo SR Clin Ter; 2019; 170(6):e472-e477. PubMed ID: 31696912 [TBL] [Abstract][Full Text] [Related]
15. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. Dangaj D; Bruand M; Grimm AJ; Ronet C; Barras D; Duttagupta PA; Lanitis E; Duraiswamy J; Tanyi JL; Benencia F; Conejo-Garcia J; Ramay HR; Montone KT; Powell DJ; Gimotty PA; Facciabene A; Jackson DG; Weber JS; Rodig SJ; Hodi SF; Kandalaft LE; Irving M; Zhang L; Foukas P; Rusakiewicz S; Delorenzi M; Coukos G Cancer Cell; 2019 Jun; 35(6):885-900.e10. PubMed ID: 31185212 [TBL] [Abstract][Full Text] [Related]
16. CXCR3, inflammation, and autoimmune diseases. Lacotte S; Brun S; Muller S; Dumortier H Ann N Y Acad Sci; 2009 Sep; 1173():310-7. PubMed ID: 19758167 [TBL] [Abstract][Full Text] [Related]
17. Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-gamma in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids. Proost P; Verpoest S; Van de Borne K; Schutyser E; Struyf S; Put W; Ronsse I; Grillet B; Opdenakker G; Van Damme J J Leukoc Biol; 2004 May; 75(5):777-84. PubMed ID: 14996826 [TBL] [Abstract][Full Text] [Related]
18. The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment. Bikfalvi A; Billottet C Am J Physiol Cell Physiol; 2020 Mar; 318(3):C542-C554. PubMed ID: 31913695 [TBL] [Abstract][Full Text] [Related]
19. Dermatomyositis and MIG. Ragusa F Clin Ter; 2019; 170(2):e142-e147. PubMed ID: 30993311 [TBL] [Abstract][Full Text] [Related]
20. Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis. Basset L; Chevalier S; Danger Y; Arshad MI; Piquet-Pellorce C; Gascan H; Samson M J Mol Med (Berl); 2015 Dec; 93(12):1355-67. PubMed ID: 26199110 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]